Didroxyprogesterone Promotes Natural Pregnancy in Infertile Patients With Endometriosis
Didroxyprogesterone Promotes Postoperative Natural Pregnancy in Infertile Patients With Mild and Moderate Endometriosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Female patients aged 22-35 who had been diagnosed with mild to moderate endometriosis by laparoscopic surgery and had undergone surgical treatment and fertility index (EFI) score ≥5 were stratified and randomized at each branch center. The study subjects were first stratified according to EFI score, which was divided into three levels: 5-6 points, 7-8 points and 9-10 points. Then the patients were divided into 2 groups in stratification according to the segmented random method. ① Dydrogesterone group: the first postoperative menstrual cycle began on the 14th to 27th day of each menstrual cycle, dydrogesterone 10mg bid oral administration, planned to use 6 menstrual cycles (if the patient conceived naturally during the medication, the drug could be stopped), and instructed the patient to try pregnancy, observation period was 12 postoperative menstrual cycles; ② Control group: postoperative medication was not used to guide patients to try pregnancy, and the observation period was 12 menstrual cycles after surgery. The subjects should be followed up for a maximum of 6 times, respectively within the first month after surgery, the first menstrual cycle D7-13 after surgery, the fourth menstrual cycle D7-13 after surgery, the seventh menstrual cycle D7-13 after surgery, the 13th menstrual cycle D7-13 after surgery, and 1-2 months after pregnancy termination.
Outcome measures: ① Pregnancy status; ②EM symptoms and recurrence related indicators: VAS score, physical examination, CA125, gynecological B-ultrasound examination results; ③ Drug safety assessment: AMH, blood routine examination, liver and kidney function, and the patient's combined drug use and possible drug-related adverse reactions were recorded.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women aged ≥ 22 years and ≤ 35 years, diagnosed as infertility and with reproductive needs;
- BMI：18.5-27.9kg/m2；
- The menstrual cycle in recent half a year is 21-35 days;
- Laparoscopic surgery was performed in certain hospitals, the intraoperative diagnosis or postoperative pathological diagnosis was em, and the EM fertility index (EFI) score was ≥ 5; .Patients agreed to conduct the study and signed informed consent.
Exclusion Criteria:
- There are contraindications to the use of didroxyprogesterone;
- Vaginal rectal septum, endometrial em, recurrent em;
- The ovarian reserve function decreased after operation, AMH < 1.1 ng / ml or premature ovarian failure;
- Unilateral or bilateral tubal obstruction or effusion;
- Combined uterine diseases: uterine malformation (single horn uterus, double horn uterus, double uterus, mediastinal uterus); Combined with adenomyosis and intrauterine adhesion;
- Chromosomal abnormalities of both husband and wife or one of them;
- Men with abnormal semen analysis results, low spermatogenic function, non obstructive azoospermia or AZF gene microdeletion; .patients with contraindications of pregnancy: uncontrolled diabetes, undiagnosed liver and kidney dysfunction, deep venous thrombosis, history of pulmonary embolism, history of cerebrovascular accident, uncontrolled hypertension, heart disease, suspicious cervical cancer, endometrial cancer, history of breast cancer or previous history, and undiagnosed vaginal bleeding;. No long-term follow-up or poor compliance, or the investigator believes that there are any factors that affect the subject's participation in the trial or result evaluation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Didroxyprogesterone treatment group
Since the first menstrual cycle after surgery, dydrogesterone was administered orally 10mg bid on the 14th to 27th day of each menstrual cycle, planned to be used for 6 menstrual cycles (if the patient conceived naturally during medication, the drug could be stopped), and the patient was instructed to try pregnancy, the observation period was 12 menstrual cycles after surgery.
|
Didroxyprogesterone group: the first menstrual cycle after operation began on the 14th to 27th day of each menstrual cycle.
Didroxyprogesterone 10mg bid was given orally.
It was planned to use 6 menstrual cycles (if the patient was naturally pregnant during the medication, the drug could be stopped), and guide the patient to try pregnancy.
The observation period was 12 menstrual cycles after operation.
Control group: no drugs were used after operation, and the patients were guided to try pregnancy.
The observation period was 12 menstrual cycles after operation.
Subjects need to complete up to 6 follow-up visits, including the first month after operation, the first menstrual cycle d7-13 after operation, the fourth menstrual cycle d7-13 after operation, the seventh menstrual cycle d7-13 after operation, the 13th menstrual cycle d7-13 after operation and 1-2 months after termination of pregnancy
Other Names:
|
|
No Intervention: control
No medication was used after surgery, and the observation period was 12 menstrual cycles after surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
pregnancy rate
Time Frame: 6 weeks
|
percentage
|
6 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-KY-026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.